Exenatide: difference between revisions
Diff·revision 7 → 8·04:57, 6 Dec 2024
Difference between revision 7 and revision 8 of Exenatide. 3 lines changed; the page grew by 454 bytes.
| Revision 7 — 14:37, 24 Nov 2024 ArchiveBot (talk) bot: add drug-class category 2,935 bytes ±0 | Revision 8 — 04:57, 6 Dec 2024 TimelineTiernan (talk) correct the dose ladder — the maintenance dose is not the maximum dose 3,389 bytes +454 | ||
|---|---|---|---|
| 25 | Glycine at position 2 provides the DPP-4 resistance. The resulting half-life of about 2.4 hours is still short — renal clearance dominates once proteolysis is removed — which is why the immediate-release product required twice-daily injection. | 25 | Glycine at position 2 provides the DPP-4 resistance. The resulting half-life of about 2.4 hours is still short — renal clearance dominates once proteolysis is removed — which is why the immediate-release product required twice-daily injection. |
| 26 | 26 | ||
| + | 27 | As a 39-residue synthetic peptide, exenatide is characterised by the ordinary battery for a synthetic peptide drug substance — chromatographic purity, [[Peptide content|peptide content]], water, counterion and related substances — rather than by the protein methods needed for a fusion construct.{{r|usp1503}} | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |
| 29 | <ref name="nielsen2004">Nielsen LL, Young AA, Parkes DG. "Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes." ''Regulatory Peptides'' 117(2):77–88 (2004). PMID 14700743.</ref> | 31 | <ref name="nielsen2004">Nielsen LL, Young AA, Parkes DG. "Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes." ''Regulatory Peptides'' 117(2):77–88 (2004). PMID 14700743.</ref> |
| 30 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 32 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 33 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 31 | 34 | ||
| 32 | {{DEFAULTSORT:Exenatide}} | 35 | {{DEFAULTSORT:Exenatide}} |